Conversion to mTOR Inhibitor to Reduce the Incidence of Cytomegalovirus Recurrence in Kidney Transplant Recipients Receiving Preemptive Treatment: A Prospective, Randomized Trial

Transplantation. 2024 Apr 1;108(4):e63. doi: 10.1097/TP.0000000000004908. Epub 2024 Jan 26.

Authors

Matthew B Roberts¹, Camille N Kotton^{2

3}

Affiliations

¹ Infectious Diseases Unit, Royal Adelaide Hospital, Adelaide, SA, Australia.
² Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA.
³ Harvard Medical School, Boston, MA.

PMID: 38277258
DOI: 10.1097/TP.0000000000004908

No abstract available

Publication types

Randomized Controlled Trial

MeSH terms

Antiviral Agents / therapeutic use
Cytomegalovirus*
Ganciclovir
Incidence
Kidney Transplantation* / adverse effects
Prospective Studies
TOR Serine-Threonine Kinases
Transplant Recipients

Substances

Ganciclovir
TOR Serine-Threonine Kinases
Antiviral Agents